In the case of NK-92, treatment with a single dose of a CAR-engineered variant targeting ErbB2 (HER2) did not induce an immune response against the effector cells in our ongoing clinical trial in glioblastoma patients [28]. The gene discussed is ERBB2; the disease is glioblastoma.